Anti-FMC63 Antibody | Precise Support for CD19 CAR Cell Therapy Research
Release Date:
2023-08-16 13:32
Introduction to the Anti-FMC63 Antibody
CD19 is currently the most widely used target in CAR-T cell therapy, and numerous studies have demonstrated that CD19 is an effective and safe target for the treatment of B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and B-cell lymphomas. FMC63 is a murine monoclonal antibody that targets human CD19. To date, the majority of reported CAR-T clinical trials have constructed CAR-T cells based on the FMC63 antibody sequence, including the two FDA-approved anti-CD19 CAR-T products, Kymriah and Yescarta. According to the “Research Guidelines on Quality Control Testing and Nonclinical Considerations for CAR-T Cell Therapy Products” issued by the National Institute for Food and Drug Control in 2018, flow cytometry should be used to assess CAR transduction positivity, with preference given to antigen-specific proteins or anti-idiotypic antibodies that exhibit superior specificity for the antigen-binding site.
Following the launch of a pan-specific G4S-positive-rate detection antibody, HeHycells Biotechnology has now introduced a unique-epitope–targeting anti-idiotypic antibody that specifically recognizes the FMC63 scFv antigenic epitope, thereby further expanding the array of assays for assessing CAR positivity. This antibody is a rabbit monoclonal antibody characterized by high affinity, high sensitivity, and excellent specificity, and has been thoroughly validated for use in flow cytometry-based detection of Anti-CD19 (FMC63) CAR expression.
Hycells Biological Anti-FMC63 Antibody
Experimental Materials and Validation Data
Cell:
293T-CAR19 stable transfectant cells
Primary antibody:
FMC-63-PE (HY-D1857F) and FMC63-APC (HY-D1858F) were added to 293T-CAR19 cells in EP tubes at a final concentration of 1 µg/mL, followed by incubation in the dark at room temperature for 30 minutes.
Secondary antibody:
Add DyLight™ 649 donkey anti-rabbit IgG (minimal cross-reactivity) antibody to the EP tube at a 1:250 dilution, and incubate in the dark at room temperature for 30 minutes.
Protein:
APC-labeled monoclonal anti-FMC63 scFv antibody and PE-labeled human CD19 (20–291) protein were each added to 293T-CAR19 cells in EP tubes at a 1:50 dilution, followed by incubation at room temperature for 30 minutes.
Different testing methods for a well-known domestic brand
FITC, PE, and APC experimental data plots
Hycells Biological Anti-FMC63 Antibody
Data plots with different PE and APC labels
Anti-FMC63 Naked Antibody Experimental Data Graph from Hycells Biotechnology
For more details on Hycells Bio’s Anti-FMC63 antibody products, please contact our sales representative. Alternatively, you can scan the QR code below to apply directly for a free sample of the Anti-FMC63 antibody.
Contact: Mr. Xie 15201775322 。
Related News
HiXpan® Cell Culture Additive: Answers to Key Questions (Part 2)
Hycell’s maximum production capacity per batch is 200–400 units of the 500 mL format, ensuring stable supply and meeting customers’ ongoing production needs.
HiXpan® Cell Culture Additive: Key Questions and Answers (Part 1)
The blood‑derived raw materials used in HiXpan® cell culture additives comply with all regulatory requirements throughout collection, ethical review, informed consent, and commercial authorization, and are supported by a fully traceable supply chain.
This paper focuses on how Hycells transforms biological variability into engineering‑level determinism through a scientifically informed blending strategy and stringent control at the collection end.
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how Hycells proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board